[1] SCHMIEDER R E, WAGNER F, MAYR M, et al. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study[J]. Eur Heart J,2017,38(44):3308-3317.
[2] PADMANABHAN S, JOE B. Towards precision medicine for hypertension: a review of genomic, epigenomic, and microbiomic effects on blood pressure in experimental rat models and humans[J]. Physiol Rev,2017,97(4):1469-1528.
[8] OTT C, JUNG T, BRIX S, et al. Hypertrophy-reduced autophagy causes cardiac dysfunction by directly impacting cardiomyocyte contractility[J]. Cells,2021,10(4):805.
[9] LI C Y,ZHOU Q,YANG L C,et al.Dual-specificity phosphatase 14 protects the heart from aortic banding-induced cardiac hypertrophy and dysfunction through inactivation of TAK1-P38MAPK/-JNK1 /2 signaling pathway[J].Basic Res Cardiol,2016,111(2) : 19.
[10] TAN X,LI J,WANG X,et al. Tanshinone ⅡA protects against cardiac hypertrophy via inhibiting calcineurin /NFATc3 pathway[J].Int J Biol Sci,2011,7(3): 383-389.
[24] MING S, KAN M, LIU L, et al. Protective effect of Shengmaiyin in myocardial hypertrophy-induced rats: a genomic analysis by 16S rDNA[J]. Evid Based Complement Alternat Med,2022,2022:3188292.
[34] REN B, FENG J, YANG N, et al. Ginsenoside Rg3 attenuates angiotensin II-induced myocardial hypertrophy through repressing NLRP3 inflammasome and oxidative stress via modulating SIRT1/NF-κB pathway[J]. Int Immunopharmacol,2021;98:107841.